New tools along with the resurgence of and renewed interest in therapeutic peptides—have reignited peptide target discovery. While chemical synthesis struggles with long, complex peptides, recombinant expression in hosts like E. coli and yeast offers a scalable and sustainable solution.
Animate Biosciences today announces new preclinical results demonstrating that AI-designed peptides generated by its AnimateIQ discovery platform significantly reduced hallmark inflammation and fibrosis signals across multiple human cell types including skin, lung, heart and liver.